Investors & Media

Pfizer and Ionis announce discontinuation of vupanorsen clinical development program

NEW YORK and CARLSBAD, Calif. , Jan. 31, 2022 /PRNewswire/ —  Pfizer Inc.  (NYSE: PFE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the discontinuation of the Pfizer -led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was

Read more
You are now leaving to visit